Modality
ERT
MOA
KRASG12Ci
Target
AuroraA
Pathway
Ferroptosis
RB
Development Pipeline
Preclinical
~Apr 2022
→ ~Jul 2023
Phase 1
Oct 2023
→ Jan 2030
Phase 1Current
NCT06626797
2,072 pts·RB
2023-10→2030-01·Terminated
2,072 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-183.8y awayInterim· RB
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P1
Termina…
Catalysts
Interim
2030-01-18 · 3.8y away
RB
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06626797 | Phase 1 | RB | Terminated | 2072 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| ARG-6988 | Argenx | Preclinical | AuroraA |